Novo Nordisk's Oral Wegovy Application Accepted in China
Novo Nordisk A/S has had its application for oral Wegovy accepted by Chinese regulators, marking a key step toward entering the country’s growing GLP-1 weight-management market. The acceptance allows Novo to pursue expansion into what analysts estimate could become a $4.46 billion market in China within five to seven years. Analysts note that an oral version of Wegovy may attract patients who prefer non-injectable treatments, potentially increasing adoption rates. Despite the regulatory milestone, approval is not guaranteed and no timeline has been provided by Novo Nordisk or Chinese regulators. The company faces competition from Eli Lilly, Pfizer, and Innovent Biologics in China’s injectable GLP-1 space, with oral Wegovy entering a competitive market rather than an untapped one. The acceptance of the application is seen as positive for long-term growth potential but does not immediately translate into revenue. Analysts remain cautious due to regulatory uncertainty and existing competition.
Topics: China market expansion GLP-1 therapies pharmaceuticals weight management